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intact rim was directly proportional to the increasing size of the Amplatzer (range 0.05 to
1.5 lbs). In the samples with segments of atrial rim excised, the force required was signif-
icantly less (range 0.2 to 0.85 lbs, p<0.02). Loss of 30% of the atrial rim segment pro-
duced a 40% mean reduction (p<0.05) in the amount of force required to dislodge the
device.
Conclusion: There is a linear relationship between the size of the Amplatzer device and
force needed to pull it through an ASD. The circumference of atrial rim is important in
securing the device. The ASD area plus excised rim area to Amplatzer area ratio of >0.6
causes a marked reduction in the stability of this device.
1019-204 Doppler Tissue Imaging Analysis of Ventricular 
Function After Surgical and Transcatheter Closure of 
Atrial Septal Defect
Yiu-Fai Cheung, Kin-shing Lun, Adolphus K. Chau, The University of Hong Kong, Hong 
Kong, Hong Kong
Background - The long-term ventricular function after surgical and transcatheter closure
of ASD is uncertain. We assessed the right ventricular (RV) and left ventricular (LV) func-
tion of children after surgical and transcatheter closure of atrial septal defect (ASD) using
Doppler tissue imaging (DTI), and compared to that of age-matched healthy controls.
Methods - Two-dimensional M-mode echocardiography, transmitral Doppler assessment
and pulsed DTI were performed in 17 patients at 5.4±3.0 years after surgical closure of
ASD (group I), 17 patients at 3.5±0.9 years after transcatheter closure by Amplatzer sep-
tal occluder (group II) and 17 healthy control subjects (group III). The RV and LV myocar-
dial performance was assessed by the DTI-derived Tei index. Results - The M-mode
measurements, transmitral Doppler indexes and LV Tei indexes did not differ among
groups. In group I, the tricuspid annular systolic and diastolic velocities and basal inter-
ventricular septum (IVS) systolic velocity were significantly lower than those of group II
and III (p<0.05). Furthermore, these patients had impairment of RV myocardial perfor-
mance as reflected by the significantly greater RV Tei index (I vs II vs III, 0.52±0.11 vs
0.40±0.10 vs 0.40±0.09, p=0.003), being related primarily to prolongation of isovolumic
contraction time (p=0.001). The RV Tei index correlated negatively with tricuspid annular
systolic velocity (r=-0.44, p=0.001) and basal IVS systolic velocity (r=-0.31, p=0.026).
Group II patients, on the other hand, had pulsed DTI indexes and myocardial perfor-
mance similar to those of normal controls. Conclusion - Surgical repair of ASD is associ-
ated with abnormal RV long-axis function and myocardial performance in the long-term.
Transcatheter device closure, on the other hand, preserves ventricular function and
should therefore be the treatment of choice for anatomically suitable defects.
1019-205 Do Patients of Advanced Age Benefit From 
Transcatheter Atrial Septal Defect Closure?
Raphael Rosenhek, Harald Gabriel, Florian Rader, Maria Heger, Thomas Binder, Gerald 
Maurer, Peter Probst, Helmut baumgartner, University of Vienna, Vienna, Austria
Background: Transcatheter atrial septal defect (ASD) closure has been shown to be fea-
sible and safe in children as well as adults. However, little is known about the clinical ben-
efit of this procedure in adult pts of advanced age.
Methods: We performed transcatheter ASD closure with the Amplatzer Septal Occluder
in 144 adults (mean age 51±17 yrs, range 17 to 82 yrs; 103 female). 39 pts were younger
than 40 yrs (group A), 57 were 40 to 60 yrs old (group B) and 48 were older than 60 yrs
(group C). Pts were followed for up to 5 years (mean FU 1.6±1.1 yrs).
Results: Successful ASD closure was achieved in all pts (occluder size 24 ± 5 mm, range
9 - 38mm). No major complications occurred. Minor complications were self-limited SVT
(4), transient AV-block (1) and transient ST-elevation (2). At follow-up, a mild residual left-
to-right shunt (Qp:Qs < 1.3) was found in 5 pts. Atrial fibrillation with conversion to SR
was observed in 9 pts. Prior to ASD closure, older patients had slightly but significantly
larger right ventricles (RV). Mean diameters (4-Ch view) were 41±6, 42±7 and 45±7mm
in group A, B and C, respectively. Pulmonary artery pressures (PAP) also increased with
age, and were 33±7, 38±10 and 53±17 mmHg in group A, B and C, respectively; p<
0.001). Three months after ASD closure a similar significant (p < 0.0001) decrease in RV
diameter was observed in all age groups with 8±6, 9±6 and 8±5 mm. PAP also
decreased significantly (p < 0.0001) in all three groups with the greatest change in the
oldest age group: 6±8, 7±9, and 11±14 mmHg in group A,B and C, respectively. The
most decrease of RV size and PAP occurred already on the first day after the interven-
tion.
Of the 81 pts who were symptomatic prior to intervention, 30 were in group B and 40 in
group C. 32 patients were markedly symptomatic (NYHA class >II) of whom 25 were in
group C. All but two pts improved. These two pts, who remained in NYHA class III, had
persistent pulmonary hypertension and severe COPD, respectively. All other pts were
asymptomatic or had only mild exertional dyspnea at FU.
Conclusion: Regression of RV size and PAP after transcatheter ASD closure can gener-
ally be expected even in patients of advanced age. These patients also show marked
symptomatic improvement.
1019-206 Reduced Adverse Event Rates After Transcatheter 
Closure of Patent Foramen Ovale When Using the 
Amplatzer-PFOTM Compared to the CardioSealTM 
Device
Sherman G. Sorensen, Peter J. Casterella, Joseph B. Muhlestein, Robert R. Pearson, 
Benjamin D. Horne, Laurie Raleigh, Jeffrey L. Anderson, Donald L. Lappe', LDS Hospital, 
Salt Lake City, UT
Background: Transcatheter closure of patent foramen ovale (PFO-C) is a low risk, out-
patient procedure for stroke prevention. Although very low death or non-fatal stroke
(CVA) rates occur after PFO-C, a variety of other neurologic sequelal (ONS) and device-
related complications (DRC) (ie thrombus, late device deformation requiring removal, or
endocarditis) do occur and may increase post-procedural testing and cost. The two avail-
able PFO-C devices, Amplatzer-PFOTM (AMP) and CardioSealTM (CS) devices differ sig-
nificantly in design, materials and deformability, but whether these differences effect post-
procedural outcome after PFO-C is unknown.
Methods: A total of 370 consecutive patients undergoing PFO-C at a single institution
between January, 2001 and May, 2003 were followed for occurrence of death, CVA, ONS
(requiring evaluation by either brain imaging or trans-esophageal echo), or DRC. Of
these, 261 (71%) (age = 50±15 yrs, males = 42%, follow-up (F/U) = 17±7 months)
received CS and 109 (29%) (age = 49±15 yrs, males = 33%, F/U = 6±2 months) received
AMP. Patients recieving CS or AMP were compared by cox hazard analysis adjusted for
baseline variables and length of follow-up.
Results: Incidence of death (3, 0.8%) and CVA (2, 0.5%) was low and did not differ
between groups. Incidence of DRC was 8 (2.2%), only occurred in the CS device and
generally occurred late (median = 11 months) during follow-up. Incidence of ONS was
significantly greater [78 (30%) versus 7 (6.4%), p<0.001] in patients receiving CS than
AMP. The Cox hazard of ONS was significantly greater for CS versus AMP [univariate
hazard ratio (HR) = 0.26 (CI=0.11-0.63, p=0.002), adjusted HR = 0.25 (CI=0.11-0.59,
p=0.001)] as well as for any adverse event [univariate HR = 0.30 (CI=0.14-0.67,
p=0.003), adjusted HR = 0.25 (CI=0.14-0.67, p=0.003)].
Conclusion: In this large single-center consecutive study of patients undergoing PFO-C,
adverse event rates were significantly reduced by the use of the Amplatzer-PFOTM com-
pared with the CardioSealTM device. The underlying reasons for these results require fur-
ther study.
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1039-199 Reduction of QRS Duration After Pulmonary Valve 
Replacement in Adult Fallot Patients Is Related to 
Degree of Reduction of Right Ventricular Volume
Bart Hooft van Huysduynen, Cees A. Swenne, Arie C. Maan, Alexander van Straten, 
Henk J. Ritsema van Eck, Martin J. Schalij, Ernst E. van der Wall, Albert de Roos, Mark 
G. Hazekamp, Hubert W. Vliegen, Leiden University Medical Center, Leiden, The 
Netherlands
Background:
Severely prolonged QRS duration in patients (pts) late after total correction of tetralogy of
Fallot (TOF) is associated with ventricular tachycardia (VT) and sudden death. Stabiliza-
tion of QRS duration on the long run has been shown after pulmonary valve replacement
(PVR), however, the short-term effects of PVR, and the relation to degree of reduction of
RV volume is unknown. Optimal timing of PVR remains subject to debate.
Methods: 26 adult TOF pts who underwent PVR were included. Standard 12 lead ECGs
were recorded before and one year after PVR and analysed by a blinded observer. QRS
duration was determined with a computer program using averaging techniques. Cardiac
MRI was performed to assess RV dimensions.
Results: QRS duration decreased in 17 pts from 148 ± 32 to 139 ± 32 ms, remained
constant: 156 ± 10 ms in 3 pts, and increased slightly in 6 pts from 149 ± 33 to 151 ± 33
ms. For the whole group, the QRS duration shortened from 149 ± 30 to 144 ± 31ms,
p<0.001. Cardiac MRI showed a RV end-diastolic volume decrease from 305 ± 87 to 210
± 62 mL (p<0.001). QRS duration correlated well with RV end-diastolic volume (r = 0.5, p
= 0.01, see figure).
Conclusion: In adult patients with TOF, late after total repair, PVR leads to a reduction of
QRS duration in the majority of patients. The degree of reduction of QRS duration is
associated with the degree of RV reduction. Improvement of this marker for VT and sud-
den death supports a less restrictive management concerning PVR in these pts. 
